Royalty Pharma plc(RPRX)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Latest News & Analysis
Royalty Pharma plc: $2B Strategic Investment in Revolution Medicines Enhances Oncology Portfolio
Royalty Pharma's $2B deal with Revolution Medicines bolsters its oncology royalties with synthetic royalty and secured loan, spotlighting strategic portfolio diversification.
Royalty Pharma plc (RPRX) $2B Revolution Medicines Deal and Financial Insights
Royalty Pharma's $2B funding deal with Revolution Medicines fuels daraxonrasib's development, impacting RPRX's growth, royalties, and strategic positioning in biopharma finance.
Royalty Pharma plc (RPRX) Strategic $2B Oncology Deal and Financial Analysis
Royalty Pharma's $2 billion deal with Revolution Medicines marks a strategic pivot in biotech funding, reshaping its financials and growth trajectory.
Royalty Pharma's $2B Daraxonrasib Bet: A Strategic Oncology Pivot
Royalty Pharma's bold $2 billion bet on daraxonrasib marks a strategic pivot into RAS-addicted cancer treatment, blending synthetic royalties with a secured loan.
Royalty Pharma (RPRX) Analysis: Strategic Moves and Guidance Raise
Royalty Pharma's strategic acquisition, guidance raise, and conference insights signal a focus on efficiency and growth, backed by strong Q1 performance.
Royalty Pharma (RPRX): Leadership, Investments, and Market View
Royalty Pharma navigates the biopharma royalty space with new leadership, strategic investments, and a resilient healthcare sector position. Investor Day insights ahead.
Royalty Pharma (RPRX): Investor Day, Biogen & Portfolio Strategy
Analysis of Royalty Pharma (RPRX): Upcoming Investor Day, Biogen collaboration impact, portfolio strategy, and financial health. Insights for investors.
Royalty Pharma (RPRX): Growth, Dividends, and Strategic Investments
Royalty Pharma (RPRX) navigates growth via strategic investments and shareholder returns. Recent collaborations, bond monetization, and dividend hikes underscore its approach.
Royalty Pharma (RPRX): Strategic Growth, Biogen Collaboration, and Shareholder Value
Royalty Pharma (RPRX) navigates the biopharmaceutical landscape through strategic capital allocation, R&D collaborations, and shareholder value initiatives. Recent Q4 results and the Biogen collaboration underscore its growth commitment.
Royalty Pharma (RPRX): Q4 2024 Results, Biogen Collaboration, and Growth Outlook
Royalty Pharma (RPRX) Q4 2024 results showcase strong financials and strategic investments, including a Biogen collaboration and dividend increase. A deep dive into growth and outlook.
Royalty Pharma (RPRX) Q4 2024: Financial Analysis and Future Outlook
Royalty Pharma (RPRX) demonstrates strong Q4 2024 performance, strategic investments, and commitment to shareholder value. Analyst consensus points to a positive outlook.